CureMetrix vs Elucid

Elucid's PlaqueIQ runs under CPT Category I code 75577, for which Medicare pays the performing site a national average of about $1,012 in imaging centers and physician offices and $951 under OPPS. Elucid bills providers per analysis, and the price is not public. The service includes human steps, since a physician sends CCTA images and trained analysts segment a 3D coronary model before the software quantifies plaque. Turnaround time is unpublished. The FDA wording for K241524 (September 2024) is plaque quantification to support clinicians, not diagnosis of disease, and a second PlaqueIQ decision, K261855, followed in September 2026.

CureMetrix reads mammograms and Elucid reads coronary CTA, so the two answer to different buyers. cmAngio flags breast arterial calcification on screening mammograms in minutes, per its homepage, and V2.0 was cleared in July 2026. CureMetrix fits a breast imaging center adding a cardiovascular finding to mammograms it already performs. Elucid fits a cardiology group or imaging center sending coronary CTAs for analysis, and its FFR-CT analysis is pending FDA review, per MassDevice.